Experimental vaccine against virus that causes ‘kissing disease’ promises promising results

vaccine trials against Epstein-Barr virus (EBV) “Promising” results were achieved in mice, according to a preliminary study published in the journal Nature Communications. This scientific advance, although still in its developmental stages, has generated great interest in the causal relationship between EBV and the virus. multiple sclerosis.

The paper, signed by researchers at the Berghof Institute for Medical Research in Australia, said “new developments are needed globally” because no vaccine has been approved to prevent the virus, which infects at least 95 percent of the population. According to “EFE”.

Previously, other vaccines have not worked well when tested in humans and animal models.Now, this vaccine targets lymph nodes, then open the silver lining “Has shown promise in mice”.

Promising Milestone: Specific Antibodies

The researchers responsible for developing the vaccine found that when the animals were given the vaccine, it Produce “effective” specific antibodies EBV and T cells, preserved for at least seven months after vaccination.

Also, scientists remember how the vaccine was designed “To really prevent multiple sclerosis

” and were able to “induce immunity” to control virus-associated tumors.

The research team will continue to work on the design of this vaccine to ensure that the effective results in mice can also be seen in humans.

Viruses of the herpes virus family are spread through saliva and can cause mononucleosis, better known as the “kissing disease,” may be a risk factor for other diseases, such as cancer of the throat and nose, or multiple sclerosis, and a growing body of research suggests that infection may be a precursor to the disease. The immune system does not eliminate Espstein-Barr virus from the organism, so it may be reactivated and spread again.

Infection with the ‘kissing disease’ virus may play a role in the development of multiple sclerosis, one of the major developments for 2022 cited in Science.